Zimmer Biomet

Current directors and officers who also hold a role at another S&P 500 company.

• Suketu UpadhyayINCY · CFOVRTX · Director
• Louis ShapiroSTE · Director
• Michael J. FarrellRMD · CEO
• Sreelakshmi KolliISRG · Director

Latest Schedule 13D/13G filing per holder. Holders that reported falling below 5% are not shown. Index funds usually report once a year.

No 5% holder filings parsed yet for this company.

Open-market purchases and sales reported on Form 4. Grants, option exercises and tax withholding are excluded.

Every 8-K with Item 5.02 (departure, election or appointment of directors and officers). The text is the first paragraph of the item.

1. Sep 8, 2026

   On September 8, 2026, Zimmer Biomet Holdings, Inc. (the “Company”) notified Kevin Thornal, Group President, Global Businesses and the Americas, that his position is being restructured. Mr. Thornal will be departing from the Company, effective on September 30, 2026. Mr. Thornal will be eligible for severance benefits under the Company’s Restated Executive Severance Plan, as amended (the “Severance Plan”). Pursuant to the Severance Plan, Mr. Thornal will receive benefits, including a lump sum amount equal to the sum of twelve months of his annual base salary plus target annual bonus, plus twelve months of his current monthly COBRA premiums. His right to receive such severance payments and benefits is conditioned upon his executing and not revoking a general release in favor of the Company.

   Read the 8-K filing
2. Apr 28, 2026

   On April 22, 2026, Suketu Upadhyay informed Zimmer Biomet Holdings, Inc. (the “Company”) of his intention to resign from the position of Chief Financial Officer and Executive Vice President – Finance, Operations and Supply Chain of the Company, effective as of April 28, 2026, to pursue a new professional opportunity. Mr. Upadhyay’s departure is not the result of any disagreement with the Company on any matter relating to its financial statements, internal control over financial reporting, operations, policies or practices. In connection with Mr. Upadhyay’s departure, Paul Stellato, Vice President, Controller and Chief Accounting Officer, has been appointed to act, along with continuing to serve in his current role, as the Company’s interim Chief Financial Officer, effective upon Mr. Upadhyay’s departure, until a permanent successor is named. In this role, Mr.

   Read the 8-K filing
3. Jan 12, 2026

   On January 8, 2026, Mark Bezjak, a named executive officer in the 2025 proxy statement of Zimmer Biomet Holdings, Inc. (the “Company”), informed the Company that he will resign his employment, including all officer positions with the Company and its affiliates, effective as of January 16, 2026, to pursue another business opportunity. As previously reported, Mr. Bezjak ceased to be an executive officer of the Company on July 1, 2025.

   Read the 8-K filing
4. Jun 3, 2025

   At the annual meeting of shareholders of Zimmer Biomet Holdings, Inc. (the “Company”) held on May 29, 2025 (the “Annual Meeting”), the Company’s shareholders approved the amended Zimmer Biomet Holdings, Inc. 2009 Stock Incentive Plan (the “SIP”). In February 2025, the Board of Directors of the Company approved proposed amendments to the SIP and directed that the amended SIP be submitted to shareholders of the Company for approval at the Annual Meeting.

   Read the 8-K filing
5. May 27, 2025

   On May 27, 2025, Zimmer Biomet Holdings, Inc. (the “Company”) announced that Kevin Thornal has been appointed to the newly-created position of Group President, Global Businesses and the Americas of the Company, effective July 1, 2025. Prior to joining the Company, Mr. Thornal, age 51, served as President and Chief Executive Officer of Nevro Corp. from April 2023, and as a member of its Board of Directors from May 2023, until the completion of its acquisition by Globus Medical, Inc. in April 2025. He previously served as the Group President of Global Diagnostic Solutions at Hologic, Inc. (“Hologic”) from April 2022 to April 2023. Mr. Thornal served in several leadership positions with increasing levels of responsibility at Hologic from 2014 to April 2023. Prior to Hologic, Mr. Thornal held several roles of increasing responsibility at Stryker Corp.

   Read the 8-K filing
6. Feb 25, 2025

   On February 25, 2025, the Board of Directors (the “Board”) of Zimmer Biomet Holdings, Inc. (the “Company”) announced that, due to the Company’s mandatory director retirement policy, Christopher Begley, the Company’s Chairman of the Board, is not eligible for nomination by the Board for election as a director at the 2025 Annual Meeting and will retire from the Board when his current term expires at such meeting. The Board, upon the recommendation of the Corporate Governance Committee, has appointed Ivan Tornos, the Company’s President, Chief Executive Officer and a director, as the Chairman of the Board, effective on May 29, 2025, the day of the 2025 Annual Meeting. Additionally, the Board has appointed Michael Farrell to be the Lead Independent Director of the Board, effective upon the commencement of Mr. Tornos’ service as Chairman.

   Read the 8-K filing
7. Jun 20, 2024

   On June 20, 2024, the Board of Directors (the “Board”) of Zimmer Biomet Holdings, Inc. (the “Company”), upon the recommendation of the Corporate Governance Committee, increased the size of the Board from ten members to eleven members and appointed Devdatt Kurdikar to fill the resulting vacancy, with a term to expire at the Company’s 2025 annual meeting of shareholders. Mr. Kurdikar has been appointed to the Corporate Governance Committee and the Compensation and Management Development Committee. There are no arrangements or understandings between Mr. Kurdikar and any other person pursuant to which Mr. Kurdikar was appointed a director of the Company, and Mr. Kurdikar has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K. As a non-employee director, Mr.

   Read the 8-K filing
8. May 15, 2024

   At the annual meeting of shareholders of Zimmer Biomet Holdings, Inc. (the “Company”) held on May 10, 2024 (the “Annual Meeting”), the Company’s shareholders approved the amended Zimmer Biomet Holdings, Inc. Employee Stock Purchase Plan (the “ESPP”). In February 2024, the Board of Directors of the Company approved proposed amendments to the ESPP and directed that the amended ESPP be submitted to shareholders of the Company for approval at the Annual Meeting. The amendments to the ESPP: • increase the number of shares available for issuance and purchase by participants under the ESPP by 10,000,000 million shares; and • modify certain other ESPP provisions to facilitate administration of the ESPP and implement best practice changes.

   Read the 8-K filing
9. Jan 5, 2024

   On January 5, 2024, the Board of Directors (the “Board”) of Zimmer Biomet Holdings, Inc. (the “Company”), upon the recommendation of the Corporate Governance Committee, increased the size of the Board from ten members to eleven members and appointed Louis A. Shapiro to fill the resulting vacancy, with a term to expire at the Company’s 2024 annual meeting of shareholders. Mr. Shapiro has been appointed to the Audit Committee and the Quality, Regulatory and Technology Committee. There are no arrangements or understandings between Mr. Shapiro and any other person pursuant to which Mr. Shapiro was appointed a director of the Company, and Mr. Shapiro has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K. As a non-employee director, Mr.

   Read the 8-K filing
10. Aug 22, 2023

    Senior Leadership Changes On August 22, 2023, Zimmer Biomet Holdings, Inc. (the “Company”) announced changes in its senior management and Board of Directors (“Board”). On August 17, 2023, Bryan C. Hanson notified the Company that he planned to step down as Chairman of the Board, President and Chief Executive Officer of the Company and as a member of the Company’s Board, all effective as of August 22, 2023. Mr. Hanson will remain with the Company as an employee in an advisory capacity at the same level of compensation through August 31, 2023. The Company did not enter into, amend or modify any material compensatory plans, arrangements or agreements in connection with Mr. Hanson’s departure. Mr. Hanson’s voluntary resignation will not trigger a right to receive any severance compensation or benefits under any compensation plans or arrangements applicable to Mr. Hanson.

    Read the 8-K filing
11. May 16, 2022

    On May 16, 2022, Zimmer Biomet Holdings, Inc. (“Zimmer Biomet” or the “Company”) announced that Paul Stellato has been appointed Vice President, Controller and Chief Accounting Officer of the Company. In this position, Mr. Stellato will serve as the Company’s principal accounting officer. Derek Davis, who served as the Company’s Interim Controller and Chief Accounting Officer and had assumed the responsibilities of the Company’s principal accounting officer during the search process that led to Mr. Stellato’s hiring, will continue in his role as the Company’s Vice President, Finance Integration. Mr. Stellato, age 47, joins Zimmer Biomet from Xylem Inc. (“Xylem”), a global provider of water technology products and services, where he served as Vice President Finance, Global Business Services from March 2019 through April 2022.

    Read the 8-K filing
12. Oct 29, 2021

    On October 29, 2021, Zimmer Biomet Holdings, Inc. (the “Company”) announced that Carrie Nichol, the Vice President, Controller and Chief Accounting Officer, and the principal accounting officer, of the Company, will be departing from the Company effective November 26, 2021. Ms. Nichol is pursuing another employment opportunity and her departure is not the result of any disagreement regarding the Company’s financial reporting or accounting policies, procedures, estimates or judgments. The Company will initiate a search for Ms. Nichol’s replacement, but in the meantime, the Company has determined that Derek Davis, the Company’s Vice President, Finance Integration, will serve as the Interim Controller and Chief Accounting Officer, and principal accounting officer, of the Company, effective upon Ms. Nichol’s departure on November 26, 2021. Mr.

    Read the 8-K filing
13. May 20, 2021

    At the annual meeting of shareholders of Zimmer Biomet Holdings, Inc. (the “Company”) held on May 14, 2021 (the “Annual Meeting”), the Company’s shareholders approved: (i) the amended Zimmer Biomet Holdings, Inc. 2009 Stock Incentive Plan (the “2009 Plan”); (ii) the amended Zimmer Biomet Holdings, Inc. Stock Plan for Non-Employee Directors (the “Director Stock Plan”); and (iii) the amended Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors (the “Deferred Compensation Plan”). In February 2021, the Board of Directors of the Company approved amendments to each of such plans and directed that the amended plans be submitted to shareholders of the Company for approval at the Annual Meeting.

    Read the 8-K filing
14. Mar 19, 2021

    On March 19, 2021, Zimmer Biomet Holdings, Inc. (the “Company”) announced that Ivan Tornos has been appointed to the newly-created position of Chief Operating Officer of the Company. Mr. Tornos, age 45, joined the Company in November 2018 as Group President, Orthopedics, and in December 2019 was appointed Group President, Global Businesses and the Americas. Prior to joining the Company, Mr. Tornos served as Worldwide President of the Global Urology, Medical and Critical Care Divisions of Becton, Dickinson and Company (“BD”) (and previously, C. R. Bard, Inc. (“Bard”)) from June 2017 until October 2018. From June 2017 until BD’s acquisition of Bard in December 2017, Mr. Tornos also continued to serve as President, Europe, Middle East and Africa (“EMEA”) of Bard, a position to which he was appointed in September 2013. Mr.

    Read the 8-K filing
15. Feb 22, 2021

    On February 18, 2021, the Board of Directors (the “Board”) of Zimmer Biomet Holdings, Inc. (the “Company”), upon the recommendation of the Corporate Governance Committee, increased the size of the Board from eleven members to twelve members and appointed Sreelakshmi Kolli to fill the resulting vacancy, with a term to expire at the Company’s 2021 annual meeting of shareholders to be held on May 14, 2021 (the “2021 Annual Meeting”). Ms. Kolli has not been appointed to any committees of the Board at this time; however, the Company expects that Ms. Kolli will be appointed to the Audit Committee and the Quality, Regulatory and Technology Committee in the near future. There are no arrangements or understandings between Ms. Kolli and any other person pursuant to which Ms. Kolli was appointed a director of the Company, and Ms.

    Read the 8-K filing

Proxy statements (DEF 14A): 2026 · 2025 · 2024 · 2023 · 2022 · 2021

From the company's 10-K XBRL data (SEC companyfacts).

People who stopped filing as an insider of this company. “Last filing” is the last Form 3/4/5, an upper bound on when they left.